Table 3.
Standardized Incidence Ratios (SIRs) for the IMRT and 3DCRT cohort compared to the general Dutch male population, adjusted for age and calendar year.
| Second Tumor Site | IMRT (n=697) | 3D-CRT (n=851) | ||||
|---|---|---|---|---|---|---|
| Observed (n) | Expected (n) | SIR (95% CI) | Observed (n) | Expected (n) | SIR (95% CI) | |
| All solid (excluding skin) | 101 | 96.4 | 1.05 (0.85–1.27) | 132 | 158.1 | 0.83 (0.70–0.99) |
| All solid non-pelvis | 73 | 53.4 | 1.37 (1.07–1.72) | 95 | 87.4 | 1.09 (0.88–1.33) |
| Anatomical Regions | ||||||
| Chest | 33 | 23.6 | 1.40 (0.96–1.96) | 40 | 39.1 | 1.02 (0.73–1.39) |
| Lung & bronchus | 23 | 18.4 | 1.25 (0.79–1.88) | 26 | 30.9 | 0.84 (0.55–1.23) |
| Abdomen | 24 | 23.5 | 1.02 (0.65–1.52) | 49 | 37.2 | 1.32 (0.97–1.74) |
| Esophagus | 8 | 3.5 | 2.29 (0.99–4.50) | 8 | 5.2 | 1.54 (0.66–3.03) |
| Stomach | 1 | 1.8 | 0.56 (0.01–3.10) | 2 | 3.3 | 0.61 (0.07–2.19) |
| Colon | 9 | 12.7 | 0.71 (0.32–1.35) | 22 | 20.5 | 1.07 (0.67–1.62) |
| Pancreas | 2 | 2.9 | 0.69 (0.08–2.49) | 9 | 4.9 | 1.84 (0.84–3.49) |
| Kidney, Renal Pelvis and Ureter | 8 | 4.4 | 1.82 (0.78–3.58) | 10 | 7 | 1.43 (0.69–2.63) |
| Pelvis | 31 | 19 | 1.63 (1.11–2.32) | 39 | 31.2 | 1.25 (0.89–1.71) |
| Bladder & Urethra | 20 | 12.5 | 1.6 (0.98–2.47) | 30 | 21 | 1.43 (0.96–2.04) |
| Rectum & Rectosigmoid | 12 | 5.8 | 2.07 (1.07–3.61) | 9 | 9.4 | 0.96 (0.44–1.82) |
| Sub-sites | ||||||
| Urinary Tract | 27 | 17.5 | 1.54 (1.02–2.24) | 41 | 28.4 | 1.44 (1.04–1.96) |
| Gastrointestinal | 37 | 30 | 1.23 (0.87–1.70) | 58 | 48.2 | 1.20 (0.91–1.56) |
| Central Nervous System | 4 | 1 | 4.00 (1.09–10.24) | 1 | 1.7 | 0.59 (0.01–3.28) |
| Unknown | 4 | 1.7 | 2.35 (0.64–6.02) | 3 | 3.4 | 0.88 (0.18–2.58) |
| Age Groups | ||||||
| Patients aged 50–69 years | ||||||
| All solid SPC | 48 | 26.1 | 1.84 (1.36–2.44) | 53 | 51.6 | 1.03 (0.77–1.34) |
| All solid SPC non-pelvis | 35 | 18.4 | 1.90 (1.32–2.65) | 39 | 36.1 | 1.08 (0.77–1.48) |
| Patients aged 70–79 years | ||||||
| All solid SPC | 56 | 50.3 | 1.11 (0.84–1.45) | 83 | 72.2 | 1.15 (0.92–1.43) |
| All solid SPC non-pelvis | 38 | 35.3 | 1.08 (0.76–1.48) | 56 | 51.3 | 1.09 (0.82–1.42) |
Observed and expected reflect number of observed and expected survivors experiencing the SPC event of interest. For SPC sub-sites, all experienced SPCs are taken into consideration. SIR=observed/expected. Evaluation period is diagnoses + 1 year up to end of exposure (end of observation period is 31-12-2019). Grouping of regions and ICD10 codes is reflected in Supplementary File 1.
Bold numbers represent significantly elevated SIRs (p < 0.05).